ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: PP11

We Suffered For Decades, But Then She Was Born
Abstract Number: PP12

Sjögren’s-Fatigue: Non-Therapeutic Lifestyle Adjustments to Help Manage My Most Problematic Symptom
Abstract Number: PP13

My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me
Abstract Number: PP14

Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Abstract Number: PP15

Toward a Frontier Beyond the Barriers of Position and Prejudice
Abstract Number: PP16

Peer Health Coaches Help Scleroderma Patients Cope with Isolation
Abstract Number: PP17

Utilizing Support Networks to Improve Patient Outcomes
Abstract Number: 0001

Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis
Abstract Number: 0002

Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases
Abstract Number: 0003

Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease
Abstract Number: 0004

CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation
Abstract Number: 0005

Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease
Abstract Number: 0006

Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile
Abstract Number: 0007

Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Abstract Number: 0008

Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].